Put companies on watchlist
bonyf NV
ISIN: BE6333353298
WKN: A3D1EU
Curious about what AI knows about Bonyf? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

bonyf NV · ISIN: BE6333353298 · EQS - Company News (14 News)
Country: Belgium · Primary market: Belgium · EQS NID: 2149994
03 June 2025 05:28PM

bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India


bonyf NV / Key word(s): Capital Increase/Expansion
bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India

03-Jun-2025 / 17:28 CET/CEST


bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India

fncls.ssp?fn=download2_file&code_str=5f0f535be0839ba2a9b5d0a906fccb17

Knokke-Heist (Belgium), 3 June 2025, 6:00 p.m.; bonyf NV (Mnemonic: MLBON), a leader in dental consumer goods, professional dental consumables and dermatological solutions, is proud to announce that Group Pharmaceuticals, a leading Indian oral health company, has become a significant stakeholder in bonyf NV. To date, Group Pharmaceuticals has acquired a total of 13.5% of bonyf’s shares, marking a strong commitment to a long-term strategic partnership. This collaboration represents a major step forward in bonyf’s global expansion and positions the company to accelerate its growth in the Indian market.

Group Pharmaceuticals is a prominent player in India’s oral healthcare sector, with a field force that directly reaches over 100,000 dentists every month. This outstanding market access creates a powerful platform for promoting bonyf’s high-performance oral care products to dental professionals and their patients.

As part of the partnership, Group Pharmaceuticals will also begin local production of selected bonyf-licensed products in India. This move ensures cost-effective manufacturing, regulatory alignment, and streamlined distribution across the region.

Importantly, this alliance reinforces dentist-led product recommendations and builds strong brand trust among patients. In addition, both companies are committed to co-developing new oral care solutions tailored to the needs of the Indian market.

Jean-Pierre Bogaert, CEO of bonyf, stated: “We view this as a very important collaboration. Group Pharmaceuticals’ strong market presence and outstanding network in India will help us realize our international growth ambitions while ensuring that our products reach millions of new patients.”

bonyf sees this strategic investment and collaboration as a key driver for sustainable international growth.

For more information, visit bonyf.com or contact investor@bonyf.com.

 

bonyf’s strengths

  • Products with patented formulations
  • Produced in Switzerland compliant with stringent international quality regulations
  • Proven clinical efficacy
  • Commercial presence in 37 countries
  • Prospects for solid growth and rapid profitability
  • A fast-growing oral and dental care market

 

About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

For more information about bonyf and its innovative oral care products, please visit www.bonyf.com.

 

bonyf

Jean-Pierre Bogaert

investor@bonyf.com

 



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: bonyf NV
Kalvekeetdijk 179, box 105
8300 Knokke-Heist
Belgium
Phone: +41 79 412 42 79
E-mail: president@bonyf.com
Internet: www.bonyf.com
ISIN: BE6333353298
EQS News ID: 2149994

 
End of Announcement - EQS News Service

2149994  03-Jun-2025 CET/CEST

MIC: XPAR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.